Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyChristine E. Brown, Behnam Badie, Darya Alizadeh et al.|New England Journal of Medicine|2016Cited by 1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group studyMarilyn L. Slovak, Frederick R. Appelbaum, Kenneth J. Kopecky et al.|Blood|2000Cited by 1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S. Topp, Hagop M. Kantarjian, Nicola Gökbuget et al.|The Lancet Oncology|2014Cited by 1.3k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent GlioblastomaChristine E. Brown, Michael C. Jensen, Behnam Badie et al.|Clinical Cancer Research|2015Cited by 754
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBrian G. Till, Oliver W. Press, Brent L. Wood et al.|Blood|2008Cited by 719